Comorbidities in heart failure
Authors:
Jiří Vítovec 1; Lenka Špinarová 1; Jindřich Špinar 2
Authors place of work:
I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně
1; Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice
2
Published in the journal:
Vnitř Lék 2018; 64(9): 867-873
Category:
Reviews
Summary
Comorbidities are important parts of care in patients with heart failure. Comorbidities, as well as their treatments, directly influence the course of heart failure. We present the most comorbidities a their therapy with regard to left ventricular dysfunction.
Key words:
comorbidities – heart failure
Zdroje
- Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>.
- Špinar J, Hradec J, Špinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Cor Vasa 2016; 58(5): 455–494.
- Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35(37): 2541–2619. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu278>.
- von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc 2014; 15(12): 866–872. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jamda.2014.09.007>.
- Suter TM, Ewer MS. Cancer drugs and the heart: Importance and management. Eur Heart J 2013; 34(15): 1102–1111. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs181>.
- Newhouse A, Jiang W. Heart failure and depression. Heart Fail Clin 2014; 10(2): 295–304. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hfc.2013.10.004>.
- Niessner A, Tamargo J., Koller L et al. Non-insulin antidabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2018; 39(24): 2274–2281. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx625>.
- Seferovic PE, Petrie MC, Filippatos GS et al. Type 2 diabetes mellitus and Heart failure: a position paper of the European Society of Cardiology. Eur J Heart Fail 2018; 20(5): 853–872. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1170>.
- Kubíčková M, Šmahelová A. Diabetes mellitus a srdeční selhání. Kardiol Rev Int Med 2014; 16(5): 352- 354.
- Vítovec J, Špinar J, Špinarová L. Empagliflozin a srdeční selhání. Hypertenze a KV prevence 2016; 5(2): 19–23.
- Giagulli VA, Moghetti P, Kaufman JM et al. Managing erectile dysfunction in heart failure. Endocr Metab Immune Disord Drug Targets 2013; 13(1): 125–134.
- Anker SD. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107(15): 1991–1997. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000065637.10517.A0>.
- Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep 2009; 6(4): 272–280.
- Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645): 1231–1239. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)61240–4>.
- Widimský J Jr, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze a KV prevence 2018; 7(Suppl): 2–22.
- Vítovec J, Špinar J, Špinarová L. Léčba anémie a nedostatku železa u chronického srdečního selhání. Kardiol Rev Int Med 2014; 16(5): 364–369.
- Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J 2015; 36(23): 1437–1444. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv010>.
- Guder G, Brenner S, Stork S et al. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail 2014; 16(12): 1–10. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.183>.
- Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347(5): 305–313. <http://dx.doi.org/10.1056/NEJMoa020245>.
- Ludka O, Kára T, Drozdová A et al. Spánková apnoe a kardiovaskulární onemocnění. Kardiol Rev Int Med 2013; 15(2): 87–93.
- Nakamura S, Asai K, Kubota Y et al. Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleep-disordered breathing: a meta-analysis. Clin Res Cardiol 2015; 104(3): 208–216. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392–014–0774–3>.
- Linhartová K. Kočková R, Línková H. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Cor Vasa 2017; 59(5): e562-e591. Dostupné z DOI: <https://doi.org/10.1016/j.crvasa.2017.10.006>.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2018 Číslo 9
Najčítanejšie v tomto čísle
- Diagnosis of heart failure: the new classification of heart failure
- Pathophysiology, causes and epidemiology of chronic heart failure
- Outpatient treatment of proximal deep vein thrombosis
- What we know about epidemiology of heart failure in Slovakia and globally